Tenaya Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
The Column Group entities report significant sales of Tenaya Therapeutics common stock, reducing their overall exposure.
NASDAQ
The Column Group entities, including managing partners Tim Kutzkey and Peter Svennilson, reported significant sales of Tenaya Therapeutics common stock in early February 2026.
NASDAQ
The Column Group's aggregate ownership in Tenaya Therapeutics has decreased by over 1% due to the issuer's recent sales of additional common stock.
NASDAQ
SCHEDULE 13D/A: The Column Group Funds Update Stake in Tenaya Therapeutics, Citing Dilution from Share Sales
The Column Group and its affiliated funds have updated their beneficial ownership in Tenaya Therapeutics, Inc., reporting a decrease in their aggregate percentage stake due to the issuer's recent share sales.
NASDAQ
SCHEDULE 13D/A: Casdin Capital Files Final 13D Amendment, Exiting Significant Stake in Tenaya Therapeutics
Casdin Capital and its affiliates have filed their final Schedule 13D amendment for Tenaya Therapeutics, Inc., indicating they no longer beneficially own more than 5% of the company's common stock.
NASDAQ
SCHEDULE 13D/A: The Column Group Increases Stake in Tenaya Therapeutics Following $25 Million Investment in Public Offering
The Column Group entities have significantly increased their beneficial ownership in Tenaya Therapeutics, Inc. to 32.0% following a $25 million investment in the company's recent public offering.